Smoking Status at Time of Melanoma Diagnosis May Impact Survival

Source: Dermatology Advisor, March 2024

Being a current smoker at the time of a clinical stage I and II primary cutaneous melanoma diagnosis was associated with an increased risk for melanoma-associated death compared with never smoking and former smoking, according to study results published in JAMA Network Open.

The findings are based on data derived from 2 randomized, prospective international post hoc trials: Multicenter Selective Lymphadenectomy trials (MSLT-I and MSLT-II); these 2 trials evaluated methods of regional draining lymph node management in clinically localized primary cutaneous melanoma.

In the current analysis, investigators used patient data from MSLT-I and MSLT-II to study associations between smoking, sentinel lymph node status, and survival in adults aged 18 to 75 years with clinical stages I and II melanoma.